SecBot SecBot

MRK drug pipeline

Merck & Co., Inc. · 20 rated drugs
$147.76
+0.6% 1-day · Nov 13
Next catalyst
Mar 22, 2027
ENFLONSIA PDUFA date · in 126 days
Typical move on FDA news
±1.3%
1-day, median of 35 events
IV rank
41
IV 28% · HV 32%
Rated drugs
20
2 bullish · 2 bearish · 1 mixed · 15 neutral
Phase 3 trials
10
0 with results posted

Upcoming catalysts

9 dated
  1. Jan 4, 2027
    sac-TMT
    Phase 3 primary completion
  2. Jan 12, 2027
    Sacituzumab Govitecan
    Phase 3 primary completion
  3. Jan 15, 2027
    9vHPV Vaccine
    Phase 3 primary completion
  4. Jan 2027
    SOC: Temozolomide
    Phase 2 primary completion
  5. Jan 31, 2027
    Pembrolizumab
    Phase 3 primary completion
  6. Feb 12, 2027
    pembrolizumab
    Phase 2 primary completion
  7. Mar 22, 2027126d
    ENFLONSIA
    PDUFA date · prevention of RSV lower respiratory tract disease in children under 2 years at increased risk
  8. Apr 22, 2027157d
    IDVYNSO
    PDUFA date · HIV-1 infection
  9. Jun 15, 2027211d
    sac-TMT
    PDUFA date · endometrial cancer

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and launched in the U.S. (June 2025). The sBLA for second-season use in high-risk children under two has a PDUFA date of March 22, 2027.

ENFLONSIA clesrovimab-cfor Updated Oct 29

126days
Next catalyst
PDUFA date · Mar 22, 2027 · prevention of RSV lower respiratory tract disease in children under 2 years at increased risk
What to watch

The next hard catalyst is the FDA PDUFA decision on the sBLA to expand ENFLONSIA's label to children under two at increased risk during their second RSV season, set for March 22, 2027. An approval would incrementally expand the addressable market but is unlikely to move Merck's shares materially given the drug's small revenue contribution relative to the company's $65B+ annual sales. The EMA review is running in parallel.

Bull case
  • ENFLONSIA is the first and only RSV preventive option that uses a single, fixed dose regardless of infant weight, a meaningful convenience advantage over Beyfortus which requires weight-based dosing.
  • Pivotal trial data showed strong efficacy: an 84.3% reduction in RSV-related hospitalizations versus placebo through 5 months (CLEVER trial), and up to 76% reduction in RSV hospitalizations per published analyses.
  • The sBLA for second-season protection in high-risk children under two (PDUFA March 22, 2027) could expand the addressable market, and the EMA has accepted a parallel application for EU approval.
Bear case
  • ENFLONSIA faces entrenched competition from Sanofi/AstraZeneca's Beyfortus (nirsevimab), which was approved in 2022 and already has first-mover advantage in the pediatric RSV prophylaxis market.
  • Forecast peak sales of roughly $892M globally by 2031 (per GlobalData) represent less than 1.5% of Merck's current annual revenue, making this drug a minor contributor to the overall investment thesis for MRK.
  • The sBLA label expansion to second-season children is not a binary event; the drug is already approved and commercializing, limiting any upside surprise.
● neutral
Impact
PhaseApproved
Time to marketAlready launched and on the market. FDA approved April 21, 2026, and the drug became available in U.S. pharmacies after May 11, 2026.

IDVYNSO doravirine / islatravir Updated Oct 29

157days
Next catalyst
PDUFA date · Apr 22, 2027 · HIV-1 infection
What to watch

IDVYNSO is now a commercial-stage launch product for Merck. The next catalyst to watch is Merck's Q4 2026 / full-year earnings (expected late January/early February 2027) for the first meaningful IDVYNSO sales trajectory data since its May 2026 U.S. launch. Consensus estimates call for $220M-$280M in 2026 launch-year sales. Any quarterly print meaningfully above or below that range could move sentiment on MRK modestly, but IDVYNSO is one of many growth drivers in Merck's diversified portfolio and is unlikely to drive a binary move on its own.

Bull case
  • IDVYNSO is the first and only FDA-approved non-INSTI, tenofovir-free, once-daily two-drug HIV regimen, giving it a unique positioning for patients who need to avoid integrase inhibitors or tenofovir.
  • Phase 3 data demonstrated non-inferior efficacy head-to-head against Gilead's market-leading three-drug regimen Biktarvy, a high bar that supports a strong clinical profile.
  • Consensus estimates project launch-year 2026 sales of $220M-$280M rising to ~$950M in 2027, with peak sales of ~$1.1B by 2030, adding a meaningful new growth leg for Merck.
Bear case
  • IDVYNSO enters a fiercely competitive HIV market dominated by Gilead's Biktarvy and ViiV Healthcare's Dovato, making market share gains difficult.
  • The drug is limited to virologically suppressed adults with no history of treatment failure or doravirine resistance, narrowing its addressable patient pool.
  • As a small molecule oral HIV drug in a crowded field, IDVYNSO faces significant pricing and payer-access headwinds.
▲ bullish
Impact
PhaseFiled/PDUFA (Phase 3 data complete; BLA under priority review)
Time to marketIf approved, sac-TMT could launch in the US as early as mid-2027, following the June 15, 2027 PDUFA date. Merck is also pursuing regulatory approvals globally based on the TroFuse-005 data.

sac-TMT sacituzumab tirumotecan Updated Oct 29

211days
Next catalyst
PDUFA date · Jun 15, 2027 · endometrial cancer
What to watch

The next hard catalyst is the PDUFA target date of June 15, 2027, for sac-TMT in previously treated advanced or recurrent endometrial cancer. Approval would mark Merck's first FDA-approved TROP2 ADC and open a multi-billion-dollar market, while a CRL (complete response letter) would set the program back significantly and raise questions about the broader TroFuse development strategy. The ESMO 2026 data were highly positive, making approval the base case, but FDA advisory committee dynamics and manufacturing questions remain unknown.

Bull case
  • Phase 3 TroFuse-005 results (presented at ESMO 2026 on Oct 26) were highly positive: sac-TMT reduced the risk of death by 32% and risk of progression or death by 41% vs chemotherapy in advanced endometrial cancer, the first TROP2 ADC to show statistically significant overall survival in this setting.
  • FDA granted priority review with a PDUFA date of June 15, 2027, plus Breakthrough Therapy designation in NSCLC, signaling strong agency interest in expediting the drug.
  • Merck has 18 ongoing global Phase 3 trials across multiple tumor types under the TroFuse program, suggesting a broad label-expansion strategy if the first indication wins approval.
Bear case
  • Merck is a $200B+ diversified pharma, so even a large drug like sac-TMT may not move the stock dramatically; the Keytruda patent cliff remains the dominant concern among analysts.
  • The TROP2 ADC space is crowded: Gilead's Trodelvy (sacituzumab govitecan) and AstraZeneca/Daiichi Sankyo's Datroway (datopotamab deruxtecan) are already approved, potentially limiting sac-TMT's pricing power and market share.
  • sac-TMT is not yet approved anywhere globally and faces standard FDA manufacturing and safety-review risks despite the priority review and Breakthrough Therapy designation.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially marketed since 2014 (GARDASIL 9).

GARDASIL human papillomavirus 9-valent vaccine, recombinant Updated Oct 29

What to watch

Watch for the confirmatory trial readout for the oropharyngeal/head-and-neck cancer indication (no date announced), which could convert the accelerated approval to full approval or, in a negative scenario, narrow the label. Also monitor quarterly Gardasil sales trends for evidence of a China demand recovery or further deterioration, and the progress of Merck's single-dose regimen trials, which could expand the addressable market if successful.

Bull case
  • GARDASIL 9 is the dominant HPV vaccine in the U.S. and most developed markets, with a strong efficacy profile covering 9 HPV strains responsible for ~90% of HPV-related cancers.
  • Q3 2026 Gardasil sales of $1.995 billion beat analyst expectations of $1.76 billion, signaling a potential recovery from the 2025 China-driven slump.
  • The expanded FDA indication for oropharyngeal and head-and-neck cancer prevention opens a large adult male market segment, and long-term efficacy data (14-18 years) reinforce the product's durability.
Bear case
  • Gardasil sales fell 39% in full-year 2025 to $5.2 billion from $8.6 billion in 2024, driven by collapsing demand in China. Merck halted China shipments in early 2026 and restructured its distribution deal with Zhifei.
  • Merck's 2026 outlook explicitly excluded any Gardasil shipments to China, and the company withdrew its prior $11 billion peak-sales target for the vaccine.
  • The oropharyngeal cancer indication is approved under accelerated approval and requires a confirmatory trial; failure to verify clinical benefit could narrow the label.
● neutral
Impact
PhaseEUA (Emergency Use Authorization) / Marketed
Time to marketAlready on the market under EUA since December 2021. Must obtain full FDA approval by June 29, 2027 or lose U.S. marketing authorization.

LAGEVRIO molnupiravir Updated Oct 29

What to watch

The next hard catalyst for LAGEVRIO is the June 29, 2027 deadline when the COVID-19 EUA declaration terminates. Merck must obtain full FDA approval (an NDA) by that date or lose the ability to market LAGEVRIO in the U.S. However, with sales already collapsing to $138M in Q3 2026 (down 64% YoY) and the drug representing a trivial fraction of Merck's $66B+ annual revenue, this binary regulatory event is unlikely to move MRK shares materially. Watch for any Merck announcement of an NDA submission for molnupiravir, which would signal intent to pursue full approval before the deadline.

Bull case
  • LAGEVRIO remains an available oral treatment option for high-risk COVID-19 patients who cannot take Paxlovid due to drug interactions, maintaining a niche market position.
  • The EUA termination deadline of June 29, 2027 gives Merck roughly 8 months to pursue full FDA approval, which could extend the product's commercial life.
  • Merck's massive diversified portfolio (Keytruda, Gardasil, Winrevair, Animal Health) means LAGEVRIO's declining sales do not threaten the company's overall financial health.
Bear case
  • Sales are collapsing rapidly: Q3 2026 LAGEVRIO sales were $138M, down 64% year-over-year from $383M in Q3 2025, and Q1 2026 was just $28M.
  • The drug still lacks full FDA approval. It operates only under Emergency Use Authorization (EUA), which HHS has announced will terminate on June 29, 2027. If Merck cannot obtain full NDA approval by then, LAGEVRIO cannot be marketed in the U.S.
  • Pfizer's Paxlovid (nirmatrelvir/ritonavir) has full FDA approval and is the market leader in oral COVID-19 antivirals, putting LAGEVRIO at a competitive disadvantage.
◆ mixed
Impact
PhaseApproved
Time to marketAlready marketed since 2006; no further approval steps needed.

ROTATEQ rotavirus vaccine, live, oral, pentavalent Updated Oct 29

What to watch

RotaTeq has no upcoming binary regulatory catalysts. The key metric to track is the trajectory of Merck's vaccine segment sales in quarterly earnings reports, which will reveal how quickly the January 2026 CDC recommendation downgrade is eroding RotaTeq utilization. Investors should also watch for any policy reversals or changes to the childhood immunization schedule under the current administration.

Bull case
  • RotaTeq is a well-established, FDA-approved vaccine with over 20 years of real-world use and a strong safety/efficacy profile.
  • The global rotavirus vaccine market is projected to grow from ~$5.6B in 2026 to ~$12.9B by 2034 (CAGR 11%), per Fortune Business Insights, providing long-term growth runway.
  • RotaTeq is the only rotavirus vaccine indicated to protect against the G2 strain, a potential differentiation vs. GSK's Rotarix.
Bear case
  • In January 2026, the CDC downgraded rotavirus vaccination from a routine universal recommendation to shared clinical decision-making, which is expected to reduce uptake significantly.
  • Bernstein analysts estimated Merck could face a potential $2 billion annual revenue hit from the CDC schedule changes, with RotaTeq as a major exposure.
  • RotaTeq generated only $711 million in worldwide sales in 2024, making it a small fraction of Merck's $65B+ total revenue, limiting its impact on the stock.
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved (FDA March 2024, EMA August 2024)

WINREVAIR sotatercept Updated Jun 30

What to watch

WINREVAIR is Merck's most important pipeline-to-launch transition since Keytruda, watch quarterly sales growth trajectory ($525M in Q1 2026, up from $280M in Q1 2025) and label expansion progress in HFpEF (Phase 2 CADENCE positive, Phase 3 planning underway). For a $325B company with Keytruda facing a 2028 patent cliff, WINREVAIR's ramp is a key swing factor in the 2028+ thesis, but MRK is far from a single-drug stock.

Bull case
  • First-in-class disease-modifying mechanism in PAH, differentiates from older vasodilator-only therapies like J&J's Uptravi/Opsumit
  • Commercial launch accelerating: sales grew from $70M (Q2 2025) to $280M (Q1 2025) to $525M (Q1 2026), according to company reports
  • Three positive Phase 3 trials (STELLAR, ZENITH, HYPERION) all showed 76% risk reduction on key endpoints; data published in NEJM
Bear case
  • Already approved, the defining binary catalyst has passed; stock moved on PDUFA in March 2024 and label update in Oct 2025
  • PAH market is crowded with entrenched competitors: J&J's Uptravi, Opsumit, Opsynvi and United Therapeutics' Adcirca, over 70% of Winrevair starters had previously used these drugs
  • Very high price (~$240,000/year list price) may face payer pushback and access hurdles despite being first-in-class
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since October 2013. First generic entered the US market on October 5, 2026.

ADEMPAS riociguat Updated Oct 29

What to watch

The first generic riociguat launched on October 5, 2026, which will erode Adempas sales and Merck's alliance revenue share over time. Merck reports Adempas/Verquvo alliance revenue as a combined line item in its quarterly filings; watch for declining contributions in upcoming earnings. No binary catalysts remain for this mature, approved drug.

Bull case
  • Adempas generated approximately EUR 745 million (USD ~$850 million) in global sales in 2025, up from EUR 721 million in 2024, showing continued growth before generic entry.
  • Adempas remains the only FDA-approved drug for chronic thromboembolic pulmonary hypertension (CTEPH), a protected indication that may slow generic erosion.
  • Merck's collaboration with Bayer gives it a share of profits from Adempas and Verquvo sales with no development cost exposure, providing low-risk alliance revenue.
Bear case
  • First generic riociguat launched in the US on October 5, 2026, by Zydus/MSN, which will erode Adempas market share and pricing power.
  • Adempas lost US patent protection in 2026, opening the door to additional generic entrants and accelerating revenue decline.
  • Merck's alliance revenue from Adempas/Verquvo was only $126 million in Q2 2025 (combined), a tiny fraction of Merck's $65 billion in total 2025 revenue, so any erosion has negligible impact on MRK stock.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized. The original BRAVECTO chewable was approved in 2014. The latest formulation, BRAVECTO Quantum (12-month injectable), was FDA-approved on July 10, 2025.

BRAVECTO fluralaner Updated Oct 29

What to watch

With no upcoming PDUFA or pivotal readout for BRAVECTO, the next event to watch for this product line is the ongoing NARB referral to the FTC and FDA over Bravecto Quantum marketing claims, which could result in labeling or advertising restrictions. Quarterly earnings reports (next: Q4 2026, late January 2027) will show whether Bravecto Quantum is gaining traction with veterinarians and whether the established chewable/topical franchise is holding market share against Zoetis's NexGard and Simparica Trio.

Bull case
  • Bravecto Quantum, approved July 2025 as the first and only once-yearly injectable flea/tick treatment for dogs, represents a significant innovation that addresses the pet owner compliance problem. It offers veterinarians a product administered in-clinic that guarantees 12 months of coverage.
  • The FDA expanded Bravecto Quantum's label in March 2026 to cover two additional tick species (Asian longhorned tick and Gulf Coast tick), broadening its addressable market in regions where those ticks are emerging threats.
  • The BRAVECTO franchise generated $1.1 billion in 2025 and is a core part of Merck Animal Health, which posted growing sales through 2026 including $1.68 billion in Q3 2026 alone.
Bear case
  • The National Advertising Review Board (NARB) referred Merck to the FTC and FDA in May 2026 for failing to comply with recommendations to modify once-a-year dosing claims for Bravecto Quantum, because the product provides only 8 months of protection against lone star ticks vs. 12 months for other species. This regulatory advertising dispute could lead to enforcement action.
  • BRAVECTO line sales were essentially flat in 2025 at $1.1 billion (1% growth), suggesting the core franchise may be maturing and facing competition from Zoetis's NexGard ($1.5B) and Simparica Trio (>$1B in U.S. sales).
  • As a small part of Merck's $65B+ total revenue (Animal Health is about $7B of that), BRAVECTO's performance has very limited ability to move Merck's stock price independently.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (since December 2015)

BRIDION sugammadex Updated Aug 28

What to watch

Bridion is an approved, mature product facing generic erosion (Lupin launched a generic in July 2026). For MRK investors, this is a non-event, Bridion represents a negligible fraction of Merck's ~$60B+ annual revenue. Watch Merck's broader pipeline (Keytruda, Gardasil) and patent cliffs instead.

Bull case
  • Bridion is the standard-of-care reversal agent for neuromuscular blockade in surgery, with a well-established safety and efficacy profile and a differentiated mechanism (selective encapsulator vs. older neostigmine).
  • The label was expanded to include pediatric patients, extending the addressable population.
  • Merck's overall analyst sentiment is positive, 25 Buy/Strong Buy ratings vs. 0 Sell, with multiple recent price-target raises (Wolfe Research to $180, Argus to $170, UBS to $175).
Bear case
  • Generic competition is eroding market share, Lupin launched a generic sugammadex injection in July 2026, directly competing with Bridion and pressuring pricing and volume.
  • Bridion is a mature, off-patent-or-near-patent product with no new growth catalysts; sales are likely in decline as generics enter the market.
  • For MRK, Bridion is a rounding error in a ~$60B+ revenue base, even a complete loss of Bridion sales would be immaterial to the stock.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2018 (FDA) and 2018 (EMA).

DELSTRIGO doravirine/lamivudine/tenofovir disoproxil fumarate Updated Oct 29

What to watch

Delstrigo is a mature, marketed product with no upcoming binary catalyst. The recent FDA sNDA approval (October 1, 2026) and European Commission authorization update (October 2026) are already priced in. Watch for quarterly sales trends and any generic entry developments as patents approach expiry in the mid-2030s, but this drug alone will not drive MRK's share price.

Bull case
  • Delstrigo is a once-daily complete regimen offering convenience for HIV patients, with a growing sales trajectory (3-year CAGR of 26.4% from FY2022 to FY2025).
  • Q1 2026 sales of $75M grew 11.9% year-over-year, showing continued commercial momentum.
  • The FDA approved a supplemental NDA in October 2026 (NDA 210807/S-019), and the European Commission updated marketing authorization in October 2026, supporting ongoing label evolution.
Bear case
  • Delstrigo faces intense competition from Gilead's Biktarvy, the market-leading single-tablet HIV regimen, which has superior efficacy and tolerability profiles.
  • The HIV treatment market is shifting toward integrase strand transfer inhibitor (INSTI)-based regimens, while Delstrigo is NNRTI-based, putting it at a structural disadvantage.
  • At roughly $300M annual run rate, Delstrigo is a rounding error within Merck's $65B+ total revenue, so even strong growth has negligible impact on MRK's stock.
▼ bearish
Impact
PhaseApproved
Time to marketAlready on the market since 2011. The drug has lost U.S. market exclusivity and faces multiple generic entrants.

DIFICID fidaxomicin Updated Oct 29

What to watch

DIFICID is a post-exclusivity product in rapid decline. For MRK investors, the drug is not a material catalyst in either direction. Watch for continued generic erosion in quarterly earnings releases, but the real MRK story remains Keytruda's patent cliff (2028) and pipeline replacement, not DIFICID.

Bull case
  • Clinical guidelines increasingly recommend fidaxomicin as first-line therapy for C. difficile infection due to lower recurrence rates versus vancomycin, which could support continued brand prescribing even with generic availability.
  • The pediatric oral suspension formulation approved in 2020 provides a differentiated product form that may face less generic competition than the tablet form.
  • Merck's massive and diversified portfolio means DIFICID's decline is easily absorbed; the company raised full-year 2026 guidance on strength in Keytruda and other products.
Bear case
  • DIFICID lost U.S. market exclusivity in July 2025 when Teva launched a generic, and sales collapsed 77% year-over-year in Q2 2026, with further erosion expected as more generics (Sandoz, Actavis, Torrent) enter.
  • The drug is a negligible part of Merck's portfolio (annual sales of roughly $250M at peak, versus $66B+ total company revenue), so any positive development has minimal impact on MRK shares.
  • Patent protection is largely exhausted; the last FDA-listed patent expires January 2028, and multiple Paragraph IV challenges have already cleared the way for generics.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2007. No further regulatory approval milestones are pending.

ISENTRESS raltegravir Updated Oct 29

What to watch

ISENTRESS is a mature, declining asset for Merck with no upcoming binary catalysts. The key dynamic to watch is the pace of generic erosion: Hetero Labs received final FDA approval for generic raltegravir 400mg in December 2024, and Lupin has tentative approval for the 600mg HD version. Continued sales declines are baked into expectations, but any faster-than-expected erosion or a major label expansion for a newer integrase inhibitor from a competitor could modestly pressure Merck's HIV franchise revenue. For Merck investors, ISENTRESS is a negligible factor relative to Keytruda, Gardasil, and Winrevair.

Bull case
  • ISENTRESS remains the only integrase inhibitor approved in the U.S. for treating HIV-1 in neonates (newborns from birth to 4 weeks of age weighing at least 2 kg), a niche but important label advantage that generics cannot easily replicate.
  • Merck has expanded the franchise with ISENTRESS HD (1200mg once-daily) and a pediatric oral suspension formulation, extending the product's lifecycle and addressing specific patient populations.
  • The drug has a well-established safety and efficacy profile with over 18 years of real-world use, which supports continued prescribing in appropriate patients, particularly in treatment-experienced populations and resource-limited settings.
Bear case
  • Generic competition is now in the market: Hetero Labs received final FDA approval for generic raltegravir 400mg on December 19, 2024, and Lupin has tentative approval for the 600mg HD version with 180-day exclusivity eligibility, which will erode branded ISENTRESS pricing and volume.
  • ISENTRESS is a first-generation integrase inhibitor with twice-daily dosing (400mg) that is losing ground to newer once-daily integrase inhibitors like dolutegravir (ViiV/GSK) and bictegravir (Gilead), which offer better resistance profiles and convenience.
  • Sales are declining: PharmaCompass data shows ISENTRESS revenue fell from $483M in 2023 to $394M in 2024, a roughly 18% decline, and the trend is likely accelerating with generic entry.
▼ bearish
Impact
PhaseApproved
Time to marketAlready marketed. Generic versions of Janumet XR launched in July 2026, and generic Janumet (non-XR) received FDA ANDA approval in 2026. The brand faces ongoing revenue erosion from generics and IRA-mandated price cuts effective January 1, 2027.

JANUMET sitagliptin and metformin hydrochloride Updated Oct 29

What to watch

Janumet is a post-peak, generically-eroded asset with no binary catalysts ahead. The IRA price cut on January 1, 2027, will further compress brand revenue, but this is well-telegraphed. For MRK investors, the focus should remain on Keytruda's Qlex launch trajectory, Gardasil demand in China, and pipeline readouts rather than the declining diabetes franchise, which is already a diminishing contributor to overall results.

Bull case
  • Janumet remains a meaningful revenue contributor: combined Januvia/Janumet franchise still generated ~$940M in Janumet sales alone in 2025, per IntelMarketResearch.
  • Merck successfully defended its sitagliptin patents in U.S. court, securing co-formulation patent protection through at least January 2029, which may limit generic competition on the exact branded formulation.
  • Merck's overall business is strong and diversified: Q3 2026 revenue of ~$18.1B and raised full-year guidance to $66.8B-$67.3B, with Keytruda and Gardasil driving growth, offsetting the diabetes franchise decline.
Bear case
  • Generic competition is already eroding sales: Par Health launched the first generic of Janumet XR in July 2026, and additional ANDA approvals for generic Janumet have been granted.
  • Sales are in freefall: combined JANUVIA/JANUMET sales declined 31% YoY to $429M in Q2 2026, and Q1 2026 saw a 28% decline to $574M, driven by U.S. generic competition and international pressure.
  • The IRA Medicare price negotiation will impose an ~85% price cut on Janumet starting January 2027, reducing the monthly cost to ~$80 from ~$527, severely compressing brand revenue.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 1971. No additional regulatory steps are needed for the current indication.

M-M-R II measles, mumps, and rubella virus vaccine live Updated Oct 29

What to watch

M-M-R II has no scheduled binary catalysts. Merck investors should watch quarterly vaccine-segment revenue trends for signs of market-share erosion to GSK's Priorix, and monitor CDC/ACIP recommendation changes that could affect overall MMR vaccination rates. The more impactful near-term drivers for MRK stock are Keytruda patent-cliff dynamics, Gardasil sales trends, and pipeline readouts in oncology and cardiometabolic drugs.

Bull case
  • M-M-R II is the most-sold MMR vaccine in the US, with over 231 million doses distributed over three decades, giving it entrenched market position and physician familiarity.
  • Rising measles outbreaks due to declining vaccination rates and vaccine hesitancy could drive increased demand for MMR vaccination, benefiting M-M-R II.
  • The global MMR vaccines market is projected to grow at a CAGR of 5.5-12.6% through the early 2030s, providing steady tailwinds for an established product.
Bear case
  • GSK's Priorix, FDA-approved in June 2022 and licensed in over 100 countries, is a direct competitor that the CDC considers fully interchangeable with M-M-R II, creating pricing and market-share pressure.
  • As a mature vaccine first approved in 1971, M-M-R II faces no patent protection and is a small, undifferentiated part of Merck's massive $65B+ portfolio, limiting its ability to move Merck's stock.
  • Potential policy changes, such as executive orders altering childhood vaccine recommendations, could reduce overall MMR vaccination rates and demand.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market since 2005.

PROQUAD measles, mumps, rubella and varicella virus vaccine live Updated Oct 29

What to watch

ProQuad has no scheduled PDUFA date, AdComm, or pivotal readout in the next 12 months. As a mature, approved vaccine, its commercial trajectory will be driven by routine pediatric immunization rates and competition from GSK's Priorix, not by any binary catalyst. For MRK investors, the drug is a negligible revenue contributor within a $67 billion portfolio dominated by Keytruda and Gardasil.

Bull case
  • ProQuad is the only MMRV combination vaccine available in the U.S. that offers both subcutaneous and intramuscular administration routes, giving it a convenience edge over GSK's Priorix (subcutaneous only).
  • The November 2024 FDA supplement approval for concomitant administration data supports broader co-administration with other routine childhood vaccines, which could support stable utilization.
  • As a well-established branded vaccine with decades of safety data, ProQuad benefits from routine CDC-recommended childhood immunization schedules and public health mandates.
Bear case
  • ProQuad is a tiny revenue contributor for Merck (the entire MMRV franchise is ~$538M vs. Merck's ~$67B total revenue), so even major label changes have negligible impact on MRK's stock.
  • The vaccine faces potential competition from GSK's Priorix, which is also an MMRV vaccine.
  • As a live-virus vaccine, ProQuad carries a black-box warning about febrile seizures in children 12-23 months, which could affect uptake versus separate MMR and varicella shots.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially marketed since 1995.

VARIVAX varicella virus vaccine live Updated Oct 29

What to watch

VARIVAX has no upcoming PDUFA date, pivotal readout, or other hard binary catalyst. As a mature, approved vaccine in Merck's broad portfolio, its commercial performance will be reported as part of Merck's quarterly vaccine segment results, but it is unlikely to drive meaningful share-price movement on its own. Investors should watch for any competitive entries or CDC immunization schedule changes that could affect the varicella vaccine market.

Bull case
  • Merck is the sole U.S. manufacturer of varicella vaccine (VARIVAX and ProQuad), giving it a captive market with no direct domestic competitor.
  • The global varicella vaccine market is projected to grow at a CAGR of roughly 5-6% through 2035, driven by expanding immunization programs in emerging economies.
  • VARIVAX has been on the market for over 30 years with an established safety and efficacy profile, making it a stable, low-risk revenue contributor.
Bear case
  • VARIVAX is a very small part of Merck's business: the combined ProQuad/M-M-R II/Varivax franchise generated roughly $538 million in 2026, less than 1% of Merck's $65B+ total revenue, so its performance has negligible impact on the stock.
  • The vaccine market faces pricing pressure and potential shifts in CDC immunization schedules that could affect volumes.
  • Global competitors such as GSK, GC Pharma, and others offer varicella vaccines in markets outside the U.S., limiting international pricing power.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since January 2021.

VERQUVO vericiguat Updated Oct 29

What to watch

VERQUVO has no upcoming binary catalyst. The VICTOR trial failure in August 2025 was the last major event. For Merck investors, the drug is a negligible revenue contributor and not a meaningful swing factor for the stock. Watch for any FDA action on a potential label expansion based on the VICTOR/VICTORIA pooled analysis, but no such filing has been announced. Merck's Q3 2026 earnings released today (Oct 29, 2026) showed total sales of $18.09 billion, with Verquvo buried within the 'Other' or alliance revenue line.

Bull case
  • VERQUVO is the first and only sGC stimulator approved for heart failure, offering a novel mechanism distinct from Entresto, SGLT2 inhibitors, and other standard therapies.
  • A pooled analysis of VICTOR and VICTORIA (11,155 patients) showed a significant reduction in cardiovascular death or heart failure hospitalization across the broad HFrEF population, suggesting potential for expanded use.
  • Adempas/Verquvo combined alliance revenue grew to $112 million in Q3 2026 from $102 million in Q3 2024, indicating steady commercial progress in Bayer's territories.
Bear case
  • VERQUVO is a very small product for Merck. In the first half of 2025, Merck recorded only $21 million in U.S. sales, far below the original peak sales projection of $300 million.
  • The Phase 3 VICTOR trial failed its primary endpoint in stable HFrEF patients, limiting the addressable population and dampening hopes for a major label expansion.
  • VERQUVO faces intense competition from Novartis' Entresto (a $8.6 billion market in 2026), SGLT2 inhibitors like Farxiga and Jardiance, and Bayer's own Kerendia, all of which have stronger clinical evidence and guideline recommendations.
● neutral
Impact
PhaseApproved
Time to marketAlready marketed since 2014. The most recent label expansion (pediatric HABP/VABP) was approved in May 2026. Patent protection extends to approximately February 2036 per FDA-listed patents.

ZERBAXA ceftolozane/tazobactam Updated Oct 29

What to watch

ZERBAXA has no upcoming PDUFA dates or pivotal readouts in the next 12 months. Investors should watch quarterly Merck earnings reports for ZERBAXA sales trends, particularly whether the May 2026 pediatric label expansion drives measurable revenue acceleration. The key competitive dynamic to monitor is how ZERBAXA fares against Avycaz and Vabomere in the hospital antibiotic market, especially for Pseudomonas coverage. For MRK investors, ZERBAXA is a minor product; the stock's primary drivers remain Keytruda, Gardasil, and the broader pipeline.

Bull case
  • ZERBAXA is a well-established hospital antibiotic with a growing addressable market as antimicrobial resistance increases, particularly against multidrug-resistant Pseudomonas aeruginosa where it is considered by some clinicians as preferred over alternatives like Avycaz (ceftazidime/avibactam).
  • The May 2026 pediatric label expansion opens a new patient population for HABP/VABP, cIAI, and cUTI, potentially supporting continued revenue growth from the estimated $252M in 2024 sales.
  • Patent protection through approximately February 2036 provides a long exclusivity runway with no near-term generic threat.
Bear case
  • ZERBAXA is a relatively small product for Merck (roughly $252M in 2024 sales versus Merck's $65B+ total revenue), so even strong sales growth would have a negligible impact on the stock.
  • The hospital antibiotic market is competitive, with branded rivals including Avycaz (ceftazidime/avibactam), Vabomere (meropenem/vaborbactam), and newer entrants, all targeting similar resistant gram-negative infections.
  • As an already-approved, marketed drug with no pending regulatory catalysts, ZERBAXA lacks the binary event that typically drives significant share-price moves for a developer.
● neutral
Impact
PhaseApproved (for CMV prophylaxis in HSCT). Phase 2 completed for lung transplant indication (NCT05041426).
Time to marketAlready approved and commercially available (FDA approval November 8, 2017). Additional indications may be pursued but no near-term timeline is defined.

PREVYMIS letermovir Updated Aug 28

What to watch

PREVYMIS is already approved and commercialized; there is no upcoming PDUFA, pivotal readout, or binary catalyst for this drug in the next 12 months. For MRK investors, PREVYMIS is a negligible standalone consideration. Focus instead on Merck's upcoming KEYTRUDA PDUFA dates (September 21, 2026) and the ifinatamab deruxtecan PDUFA (October 10, 2026) for material catalysts.

Bull case
  • PREVYMIS fills a specific niche as a CMV terminase inhibitor with a novel mechanism, less bone-marrow toxicity than conventional therapies like ganciclovir, making it a preferred option for post-transplant prophylaxis where marrow recovery is critical.
  • A completed Phase 2 trial (NCT05041426) studying letermovir for CMV prevention after lung transplantation (March 2025 completion) suggests potential label expansion into additional solid-organ transplant indications, which could incrementally grow the product's addressable market.
  • As an approved, commercially available drug with a clean safety profile, PREVYMIS generates steady recurring revenue for Merck with no binary clinical risk.
Bear case
  • PREVYMIS is a minor revenue contributor within Merck's massive portfolio, MRK's value is overwhelmingly driven by KEYTRUDA (~$25B+/year) and other oncology assets, not anti-infective products like PREVYMIS.
  • No upcoming PDUFA or label-expansion catalyst for PREVYMIS; the drug's commercial profile is mature and incremental growth from new indications (e.g., lung transplant prophylaxis) faces clinical and regulatory timelines unlikely to move Merck's stock materially.
  • Competing CMV antivirals like valganciclovir/ganciclovir remain standard-of-care alternatives, limiting PREVYMIS's market penetration upside.

Other drugs in filings and trials

no drug report yet
  • ifinatamab deruxtecan (I-DXd) Last: Priority review · Oct 10, 2026
  • WELIREG Last: PDUFA decision · Oct 4, 2026
  • KEYTRUDA Last: PDUFA decision · Sep 21, 2026
  • Raludotatug Deruxtecan Last: Breakthrough designation · Apr 7, 2026 1 trial
  • MK-1406 Last: NDA filed · Feb 1, 2026
  • BLA761495 Last: Approval · Oct 15, 2025
  • KEYTRUDA QLEX Last: Approval · Sep 19, 2025
  • NOXAFIL POWDERMIX KIT Last: Approval · May 31, 2021
  • RECARBRIO Last: Approval · Jul 16, 2019
  • PIFELTRO Last: Approval · Aug 30, 2018
  • STEGLUJAN Last: Approval · Dec 19, 2017
  • ZINPLAVA Last: Approval · Oct 21, 2016
  • ZEPATIER Last: Approval · Jan 28, 2016
  • EMEND Last: Approval · Dec 17, 2015
  • DUTREBIS Last: Approval · Feb 6, 2015
  • BELSOMRA Last: Approval · Aug 13, 2014
  • NOXAFIL Last: Approval · Mar 13, 2014
  • 9vHPV Vaccine 1 trial
  • Avelumab 1 trial
  • Ivermectin 1 trial
  • MK-1167 1 trial
  • Pembrolizumab 1 trial
  • Pembrolizumab injection 1 trial
  • Pembrolizumab, paclitaxel 1 trial
  • SOC: Temozolomide 1 trial
  • Suvorexant 1 trial

Past FDA events & how the stock moved

35 events
DateDrugEvent1 day5 days
Oct 10, 2026ifinatamab deruxtecan (I-DXd)Priority review−0.1%+0.2%
Oct 10, 2026ifinatamab deruxtecanPDUFA decision−0.1%+0.2%
Oct 4, 2026WELIREGPDUFA decision−3.3%+0.9%
Sep 21, 2026KEYTRUDAPDUFA decision+2.8%+1.2%
Aug 17, 2026KEYTRUDAPriority review−0.5%+10.9%
Aug 17, 2026KEYTRUDAPDUFA decision−0.5%+10.9%
Jun 19, 2026WELIREGPDUFA decision+1.4%+13.0%
Apr 7, 2026KEYTRUDAPDUFA decision+1.9%−0.7%
Apr 7, 2026KEYTRUDAPriority review+1.9%−0.7%
Apr 7, 2026Raludotatug DeruxtecanBreakthrough designation+1.9%−0.7%
Apr 1, 2026KEYTRUDAApproval+0.5%+2.0%
Feb 20, 2026KEYTRUDAPDUFA decision+1.6%+1.6%
Feb 1, 2026MK-1406NDA filed+2.8%+10.6%
Oct 15, 2025BLA761495Approval−0.9%+3.4%
Sep 19, 2025KEYTRUDA QLEXApproval−1.4%−3.6%
Jun 9, 2025ENFLONSIAApproval+3.0%+3.5%
Mar 26, 2024WINREVAIRApproval+5.1%+3.7%
Aug 13, 2021WELIREGApproval+2.5%+3.5%
May 31, 2021NOXAFIL POWDERMIX KITApproval−0.9%+0.5%
Jul 16, 2019RECARBRIOApproval+1.2%+1.3%
Aug 30, 2018PIFELTROApproval−0.3%+1.3%
Dec 19, 2017STEGLUJANApproval−0.2%+0.2%
Nov 8, 2017PREVYMISApproval+1.1%−1.4%
Oct 21, 2016ZINPLAVAApproval−1.9%−5.0%
Jan 28, 2016ZEPATIERApproval+0.6%−3.5%
Dec 17, 2015EMENDApproval−4.4%−2.2%
Dec 15, 2015BRIDIONApproval+3.5%−0.2%
Feb 6, 2015DUTREBISApproval−1.4%−0.6%
Sep 4, 2014KEYTRUDAApproval+1.2%+0.1%
Aug 13, 2014BELSOMRAApproval+3.1%+4.3%
Mar 13, 2014NOXAFILApproval−1.2%−1.4%
Dec 20, 2013ISENTRESSApproval+1.2%+2.4%
Nov 25, 2013NOXAFILApproval+1.3%+1.7%
Feb 2, 2012JANUMETApproval−0.7%−1.2%
Dec 21, 2011ISENTRESSApproval+1.3%+1.8%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
pembrolizumabSafety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Phase 2Active not recruiting340Feb 12, 2027
PembrolizumabEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)Phase 3Active not recruiting520Jan 31, 2027
9vHPV VaccineEfficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)Phase 3Active not recruiting6,033Jan 15, 2027
Sacituzumab GovitecanStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Phase 3Active not recruiting614Jan 12, 2027
sac-TMTA Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Phase 3Active not recruiting450Jan 4, 2027
SOC: TemozolomideA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With GlioblastomaPhase 2Active not recruiting99Jan 2027
Keytruda Injectable ProductMetastatic Solid Cancer Clinical TrialPhase 2Completed32Nov 10, 2026
Pembrolizumab injectionMolecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)Phase 2Terminated22Oct 1, 2026
sac-TMTA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)Phase 2Completed35Sep 30, 2026
PREVYMISDe-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant RecipientsPhase 3Completed30Sep 1, 2026
ONC-392ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerPhase 2Active not recruiting58Aug 30, 2026
AvelumabAvelumab Program Rollover StudyPhase 3Active not recruiting205Aug 21, 2026
GSK2636771Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossPhase 2Completed28Aug 20, 2026
Raludotatug Deruxtecan (R-DXd)A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)Phase 2Active not recruiting160Aug 18, 2026
Ensifentrine 3 mgClinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)Phase 2Completed497Aug 17, 2026
Tuvusertib (M1774)Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)Phase 2Completed63Aug 11, 2026
PembrolizumabSubstudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Phase 2Completed393Aug 10, 2026
SuvorexantSuvorexant as an Adjunct to Buprenorphine in Persons Who Use FentanylPhase 2Completed76Aug 3, 2026
—A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)Phase 2Completed85Aug 3, 2026
IV TulisokibartA Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)Phase 3Active not recruiting1,020Aug 1, 2026
PembrolizumabEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)Phase 3Active not recruiting1,397Jul 31, 2026
PembrolizumabSubstudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Phase 2Completed263Jul 23, 2026
BelzutifanA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)Phase 2Active not recruiting60Jul 21, 2026
M1774Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)Phase 2Completed61Jul 15, 2026
PembrolizumabEvaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric AdenocarcinomaPhase 2Completed31Jul 15, 2026
PembrolizumabNeoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast CancerPhase 2Completed31Jul 7, 2026
PembrolizumabStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Phase 3Active not recruiting870Jul 6, 2026
IvermectinEfficacy of Ivermectin in the Treatment of Plane WartsPhase 2Completed80Jul 1, 2026
ANV600A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)Phase 2Completed63Jun 22, 2026
Pembrolizumab, paclitaxelPembrolizumab and Paclitaxel in Hypermutated Breast CancerPhase 2Completed52Jun 19, 2026
pembrolizumab/vibostolimabStudy of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)Phase 3Completed610Jun 15, 2026
OlaparibStudy of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)Phase 2Completed333Jun 8, 2026
MK-1167A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)Phase 2Terminated369Jun 5, 2026
200 mg PembrolizumabAn Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid TumorsPhase 2Active not recruiting23Jun 2026
PembrolizumabSubstudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)Phase 2Completed335May 18, 2026
CetuximabPhase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRCPhase 2Completed16May 12, 2026
ASP1570A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid TumorsPhase 2Terminated226May 11, 2026
Nab-paclitaxelMulti-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Phase 2Completed · results36May 7, 2026
PembrolizumabRADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose RadiotherapyPhase 2Completed6May 1, 2026
PembrolizumabA Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial CarcinosarcomaPhase 2Completed26Apr 24, 2026